Danaher Corp
Close on Oct 30, 2026Market cap $163.25BP/E 41.2Yield –
Danaher Total Company Core Sales Growth (Non-GAAP) by Year
Total Company Core Sales Growth (Non-GAAP) (%)
Danaher Total Company Core Sales Growth (Non-GAAP): 2.0% in FY2025, up 3.5 pts from a year earlier.
Where the FY2025 figure comes from
Source: Danaher IR — nongaap_2025Q4 ↗
Core operating metric reflecting constant-currency organic revenue growth of segments/subsidiaries owned for ≥ 1 year.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Company Core Sales Growth (Non-GAAP) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2.0% | +3.5 pts | Danaher IR — nongaap_2025Q4 ↗ |
| FY2024 | Dec 31, 2024 | -1.5% | +8.5 pts | Danaher IR — nongaap_2024Q4 ↗ |
| FY2023 | Dec 31, 2023 | -10.0% | -20.0 pts | Danaher IR — nongaap_2023Q4 ↗ |
| FY2022 | Dec 31, 2022 | 10.0% | – | Danaher IR — nongaap_ex_veralto ↗ |
Breakdown
What makes up total Company Core Sales Growth (Non-GAAP)
- Core Growth ex-Respiratory2.5% · FY2025
- Contribution / Headwind from Cepheid Respiratory Testing to Total Company Core Sales Growth0.5% · FY2025
- Base Business Core Sales Growth (Legacy FY2021Q4–FY2023Q4: Base Business ex-COVID Testing & Vx/Tx)-0.5% · FY2023
- COVID-19 Testing & Vaccines/Therapeutics Demand Impact (Legacy FY2021Q4–FY2023Q3)–
- Price Realization Impact on Total Company Sales Growth (10-K)0.5% · FY2025
- Acquisitions Impact on Total Company Sales Growth (Annual series; quarters without M&A are left blank by the company)0.0% · FY2025
- Currency Exchange Impact-1.0% · FY2025
- Reported GAAP Sales Growth3.0% · FY2025
Cite this data
StockData. (2026). Danaher Total Company Core Sales Growth (Non-GAAP) (%), annual FY2022–FY2025 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/core-sales-growth-total
See every metric in the Danaher KPI table. Data updated Nov 2, 2026.